Aegerion Pharmaceuticals
AEGR
AEGR was delisted on the 29th of November, 2016.
99 hedge funds and large institutions have $865M invested in Aegerion Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 26 increasing their positions, 33 reducing their positions, and 18 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
22% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 18
20% more capital invested
Capital invested by funds: $721M → $865M (+$144M)
4% more funds holding
Funds holding: 95 → 99 (+4)
21% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 33
28% less call options, than puts
Call options by funds: $14.2M | Put options by funds: $19.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$41.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$21.7M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$16.8M |
| 4 |
PA
Perceptive Advisors
New York
|
+$9.7M |
| 5 |
HS
HighVista Strategies
Boston,
Massachusetts
|
+$6.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$38.8M |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$15.2M |
| 3 |
PC
PointState Capital
New York
|
-$12.6M |
| 4 |
Goldman Sachs
New York
|
-$11.5M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$11M |
AEGR Hedge Fund Activity: Q1 2015 in Review
99 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Aegerion Pharmaceuticals (AEGR) for Q1 2015, worth a combined $865M — up 20% from $721M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new AEGR positions and 18 closed out — a net gain of 4 holders — while 26 added to existing stakes and 33 trimmed.
The largest buyer was Sarissa Capital Management, opening a new position worth an estimated $41.7M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $38.8M sold.
- 99 institutional investors held Aegerion Pharmaceuticals (AEGR) as of Q1 2015, up from 95 in Q4 2014.
- Funds reported $865M of Aegerion Pharmaceuticals stock for Q1 2015, up 20% quarter-over-quarter.
- 22 funds opened new Aegerion Pharmaceuticals positions in Q1 2015 and 18 closed out, a net change of +4 holders.
- The largest Aegerion Pharmaceuticals buyer in Q1 2015 was Sarissa Capital Management, an estimated $41.7M added.
- The largest Aegerion Pharmaceuticals seller in Q1 2015 was Point72 Asset Management, an estimated $38.8M sold.
Based on aggregated 13F filings for Q1 2015.